Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000–2013: Vaccine program impact assessment  by Wormsbecker, A.E. et al.
E
(
A
a
b
c
d
F
e
a
A
R
R
A
A
K
N
M
M
P
E
M
c
P
c
P
1
k
n
h
0
nVaccine 33 (2015) 5678–5683
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
pidemiology  of  serogroup  C  and  Y  invasive  meningococcal  disease
IMD)  in  Ontario,  2000–2013:  Vaccine  program  impact  assessment
.E.  Wormsbeckera,b,  K.  Wonga, F.B.  Jamiesonc,d,  N.S.  Crowcrofta,d,e,  S.L.  Deeksa,e,∗
Public Health Ontario, 480 University Avenue, Suite 300, Toronto, ON, Canada M5G  1V2
Division of Paediatric Medicine, Hospital for Sick Children, 555 University Avenue, Black Wing, 10th Floor, Toronto, ON, Canada M5G  1X8
Public Health Ontario Laboratories, 661 University Avenue, Suite 1701, Toronto, ON, Canada M5G 1M1
Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Medical Sciences Building, 1 King’s College Circle, 6th
loor,  Toronto, ON, Canada M5S  1A8
Dalla Lana School of Public Health, University of Toronto, Health Science Building, 155 College Street, 6th Floor, Toronto, ON, Canada M5T  3M7
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 24 December 2014
eceived in revised form 7 August 2015
ccepted 10 August 2015
vailable online 20 August 2015
eywords:
eisseria meningitidis
eningococcal vaccines
eningococcal infections
ublic health
pidemiology
a  b  s  t  r  a  c  t
Objectives:  A  publicly-funded  meningococcal  serogroup  C  conjugate  vaccine  (MCCV)  program  was  intro-
duced  in  Ontario,  in 2004/2005  for 1-year-old  children  as  well  as adolescents  (approximately  12  years
old).  In 2009,  quadrivalent  meningococcal  conjugate  vaccine  (MCV4)  replaced  MCCV  for  grade  seven
students.  Our objective  was  to determine  meningococcal  vaccine  program  impact  on  reported  cases  of
serogroup  C and  Y invasive  meningococcal  disease  (IMD)  at the  population  level  in  Ontario,  Canada.
Methods:  Data  were  obtained  from  the  Ontario  reportable  diseases  system,  the  integrated  Public  Health
Information  System  (iPHIS),  and  Public  Health  Ontario  Laboratories  (PHOL)  for  2000–2013.  Descriptive
epidemiologic  analyses,  including  age-speciﬁc  rates  for age  groups  based  on  program  eligibility,  were  con-
ducted.  Changes  over  the  14-year  observation  period  and  comparison  of  pre-  and post-program  periods
for MCCV  and  MCV4  were  assessed.  Analyses  were  conducted  using  SAS  9.3.
Results: There  were  161  serogroup  C IMD  cases  and  its annual  incidence  decreased  signiﬁcantly  over  time
(17.2%  reduction  per  year  [95%  CI: 13.4  to  20.7]).  The  incidence  of  serogroup  C  IMD decreased  signiﬁcantly
in  children  aged  1–17  years  in  the  post-program  period,  based  on  age-speciﬁc  incidence  rate  ratios  (IRRs)
and their  95%  conﬁdence  intervals  (CIs).  Adolescents  12–16  years  had the  lowest  serogroup  C IRR (0.07
[95%  CI:  0.01 to 0.55]);  the  rate  decreased  more  than  14-fold  between  the  pre-  and  post-periods.  There
were  187  serogroup  Y  IMD  cases  and  there  was  a non-signiﬁcant  1.6%  reduction  per  year  [95%  CI: −1.9
to  5.1])  over  the  surveillance  period.  Likewise,  there  was a non-signiﬁcant  decrease  in  serogroup  Y  IMD
among  persons  12–16  years  (MCV4  eligible)  in  the post-program  period.
Conclusions:  Reductions  in serogroup  C  IMD  among  program  eligible  and  ineligible  age  groups  suggest
both  direct  and  indirect  MCCV  vaccine  program  impact.  Continued  surveillance  of IMD  in  Ontario  is
important  to further  assess  MCV4 program  impact.
ht  © 2Crown  CopyrigAbbreviations: IMD, invasive meningococcal disease; CFR, case fatality ratio;
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1. Introduction
Invasive meningococcal disease (IMD) is an uncommon but
serious infection. Meningococcal serogroup C conjugate vaccines
(MCCVs) were approved in Canada in 2001 and subsequently a
single dose publicly-funded program was  introduced in Ontario
(population 13.5 million, 2013 [1]) for children 12 months of age
and for adolescents. The toddler program began in September
2004 and is delivered predominantly by health care providers,
whereas the adolescent program started in January 2005 and is
given to grade seven students (approximately 12 years) through
schools by public health nurses. There was no formal, organized
catch-up program for either age group. In the fall of 2009, quadriva-
lent meningococcal conjugate vaccine (MCV4), protecting against
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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erogroups A, C, Y, and W,  replaced MCCV in the school-based pro-
ram [2,3]. MCCV and MCV4 coverage among 7-year-olds and grade
even students was estimated to be 81.5% and 89.4%, respectively
n the 2012/2013 school year [4].
Our objective was to study the population impact of the vacci-
ation programs, on serogroup C and Y disease, through a 14-year
nalysis of IMD  in Ontario.
. Methods
The surveillance period was January 1, 2000 to December 31,
013. Data were obtained from our reportable diseases system,
he integrated Public Health Information System (iPHIS), and Public
ealth Ontario Laboratories (PHOL), the province’s reference lab-
ratory. Although the data sets are not independent, data were
inked as previous analysis revealed a small proportion of labo-
atory conﬁrmed cases may  not be reported through iPHIS and
PHIS records may  be missing laboratory information, particularly
erogroup [5].
IMD  is a legally reportable disease in Ontario. Case information
as entered into iPHIS by local public health agencies. Analysis
as restricted to cases meeting Ontario’s surveillance case deﬁ-
ition for IMD  the year they occurred. The deﬁnition changed in
009 to differentiate probable cases (clinical syndrome and Neis-
eria meningitidis antigen in the cerebrospinal ﬂuid [CSF]) from
onﬁrmed cases, both of which meet the provincial surveillance
ase deﬁnition1.
PHOL determines serogroup for all viable N. meningitidis iso-
ates in the province and collects a minimum data set including
ge, sex, type of sample, and laboratory results. Serogrouping
as performed by bacterial agglutination with rabbit anti-sera
gainst meningococcal capsular antigens. Where viable cultures
ere not available, meningococcus was identiﬁed and serogroups
genogroups) A, B, C, X, W,  or Y were determined by polymerase
hain reaction (PCR) [6]. Since 2008, PHOL has conducted PCR when
 case is clinically consistent with IMD  or when a referring labora-
ory has failed to grow N. meningitidis in culture and IMD  remains
uspected [7].
We  performed deterministic linkage for records from 2011 to
013, and probabilistic linkage for years prior to 2011. Probabilistic
inkage of anonymized iPHIS and PHOL data was conducted using
dentiﬁers common to both data sets: age (PHOL) or date of birth
iPHIS), sex, serogroup and date of onset or specimen collection. In
ddition, the identiﬁers “submitting laboratory or sender” (PHOL)
nd “responsible health unit” (iPHIS) were added and matched
ased on postal codes. In 2011, reportable disease surveillance
unctions were transferred from the Ontario Ministry of Health and
1 Ontario’s surveillance case deﬁnition for conﬁrmed invasive meningococcal
isease. Prior to April 2009, a conﬁrmed case of IMD  was deﬁned as: “Isolation
f  Neisseria meningitidis from a normally sterile site, or, signs and symptoms of
eningococcemia (purpura fulminans) without culture conﬁrmation, or, signs and
ymptoms of meningitis with one of (a) antigen detection from CSF or serum, usu-
lly  by latex agglutination; (b)detection of gram negative diplococci in CSF, blood
r  skin lesions; (c) detection of N. meningitidis from serogroup-speciﬁc polymerase
hain reaction [1].” After April 28th 2009, the case deﬁnition changed to require
aboratory conﬁrmation. The current deﬁnition of conﬁrmed IMD is “isolation of N.
eningitidis from a normally sterile site, or, detection of N. meningitidis DNA by a
alidated nucleic acid ampliﬁcation test from a normally sterile site [2].” In 2009, a
eﬁnition for probable IMD  was added, accounting for the removal of antigen detec-
ion  from the conﬁrmed IMD  deﬁnition. A probable case of IMD is, “Invasive disease
ith purpura fulminans or petechiae in the absence of a positive blood culture and
o apparent cause with demonstration of N. meningitidis antigen in the CSF [2].”
1) Ministry of Health and Long-Term Care, Public Health Division. iPHIS Manual.
oronto, ON: Queen’s Printer for Ontario: 2005. (2) Ministry of Health and Long-
erm Care, Public Health Division. Infectious Diseases Protocol, 2009. Appendix B:
rovincial Case Deﬁnitions for Reportable Diseases. Toronto, ON: Queen’s Printer for
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Long-Term Care to Public Health Ontario (PHO), which allowed us
to access personal identiﬁers from iPHIS and perform determin-
istic linkage. Records that remained unmatched were included in
the ﬁnal dataset. iPHIS variables in the linked dataset were year,
serogroup, date of birth, sex, immunization status and outcome.
PHOL variables were year, serogroup, age, and sex. When data were
available in both iPHIS and PHOL, demographics were taken from
iPHIS and laboratory information was taken from PHOL.
Based on vaccine program implementation dates, we  deﬁned
2000–2004 as the pre-MCCV program era and 2005–2013 as the
post-MCCV program era. For MCV4, the pre-program period was
2000–2009 and the post-program period was 2010–2013. We
chose particular age bands to examine age-speciﬁc rates based
on program eligibility. For serogroup C IMD, by the end of the
surveillance period (2013) all individuals under 22 years were eli-
gible to participate in either the toddler or school-based programs,
although some may  not have reached the age of vaccination. Adults
22 years and over were not eligible for the routine toddler or
school-based programs during this period. Individuals 12–16 years
were important for examination of the early impact of MCV4 on
serogroup Y IMD  as by 2013, only adolescents 12–16 years were
eligible to have participated in the MCV4 program, while other age
groups were not. Due to low case numbers, adult age groups were
collapsed together.
We conducted descriptive analyses and calculated incidence per
100,000 population using annual population denominators from
Statistics Canada (2000–2013) obtained through intelliHEALTH
Ontario and the Ontario Ministry of Health and Long-Term Care.
Statistical signiﬁcance was  assessed by Poisson regression
to evaluate changes in incidence over time; the two-sided
Kolmogrov–Smirnov test to compare age distributions between
eras; and Chi Square and Fisher’s exact test to compare propor-
tions. We  calculated age-speciﬁc risk differences between periods
and determined relative risks of serogroups C and Y IMD  in their
respective post-program periods compared to pre-program peri-
ods using incidence rate ratios (IRRs) and 95% conﬁdence intervals
(CIs). We performed statistical analysis in SAS version 9.3 (SAS Insti-
tute, Cary, NC, USA). Sensitivity analyses were conducted to explore
the impact of missing outcome and serogroup information on case
fatality ratio (CFR).
This project was  not submitted for research ethics approval as
the activities described here were conducted as part of the legis-
lated mandate of PHO to inform and enhance healthy public policy
and public health planning, evaluation and action (Ontario Agency
for Health Protection and Promotion Act, SO 2007, c 10) and are
therefore considered practice, not research.
3. Results
3.1. Data linkage
The PHOL and IMD  probabilistic record linkage for 2000–2010
has been presented elsewhere [5]. Brieﬂy, probabilistic linkage
yielded 713 unique IMD  cases in Ontario between 2000 and 2010.
There were 31 unique PHOL records (4.3%), 131 (18.4%) unique
iPHIS records and 551 matched records (77.3%). The deterministic
linkage for 2011 to 2013 yielded 102 cases (1 PHOL only, 10 iPHIS
only and 91 matched). Therefore, for the entire period between
2000 and 2013 our dataset included 815 unique IMD  cases (32
[3.9%] in PHOL only, 141 [17.3%] in iPHIS only and 642 [78.8%]
matched). One hundred nineteen cases occurred prior to the change
in case deﬁnition and only 9.4% (77/815) were identiﬁed by PCR
rather than culture, however this increased from 8.3% between
2000 and 2010 to 17.8% between 2011 and 2013.
Among matched records, only one had two different serogroups
reported and the serogroup identiﬁed by PHOL was  used in the
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anada,  by serogroup (B, C, W and Y), from 2000 to 2013.
nal dataset. There were 18 iPHIS cases that had no informa-
ion on serogroup but serogroup was found in matched PHOL
ecords. Serogroup was unspeciﬁed for most unmatched iPHIS
ecords (96/141, 68.1%). Matching of iPHIS cases to PHOL appeared
o improve over time. The proportion of unmatched iPHIS cases
anged from 38% (41/106) in 2001 to 2.3% (1/43) in 2011.
.2. Epidemiology of IMD  (all serogroups)
Among the 815 unique cases (810 conﬁrmed, ﬁve probable) of
MD, serogroup B occurred most frequently (n = 307), followed in
escending order by serogroups Y (n = 187), C (n = 161), W (n = 54),
 (n = 4) and Z (n = 1). In addition, 101 cases with unspeciﬁed
erogroup were identiﬁed (96/101 [95%] iPHIS records not matched
o PHOL). Rates of IMD  by year and serogroup are presented in Fig. 1.
.3. Epidemiology of serogroup C IMD  cases
Six of the 161 serogroup C IMD  cases had only PHOL records, 14
ere from iPHIS only and 141 (87.6%) were matched. Over the 14-
ear period, incidence decreased signiﬁcantly (17.2% reduction per
ear [95% CI: 13.4 to 20.7]) from a high of 0.30 per 100,000 in 2001
o a low of 0.01 per 100,000 in 2013. Age ranged from 18 weeks to
ig. 2. Annualized age-speciﬁc incidence of serogroup C IMD  in Ontario, pre-MCCV progr
peciﬁc  incidences per 100,000 population of serogroup C IMD  by age in Ontario. Compa
rogram in 2000–2004 and post MCCV program in 2005–2013. Differences between the al incidence per 100,000 population for invasive meningococcal disease in Ontario,
94 years (median 25.6 years); with 7.5% occurring among those less
than ﬁve years. Only four cases occurred among infants less than
one year over the surveillance period. Half of the cases (50.3%) were
female and cases occurred throughout the province. Immunization
information was  missing for 160/161 serogroup C cases. The single
case with known status was unimmunized.
Outcome (survived versus died) was  unknown for 6/161
serogroup C IMD  cases, all of whom were adults ≥21 years. Among
the remaining 155, 27 died, yielding an overall CFR of 17.4%, with
no signiﬁcant variation with age (p = 0.51). In a sensitivity analy-
sis assuming all six cases with missing outcome died, overall CFR
for serogroup C IMD  increased to 22.5% (33 deaths). Conversely,
should these cases all have lived, CFR would decrease to 16.8% (27
deaths). Further, had all 101 cases (93 lived, 8 died) with unspec-
iﬁed serogroup during the surveillance period been serogroup C,
the CFR would have been 13.4% (35/262). CFR for serogroup C cases
with known outcome decreased non-signiﬁcantly from 20.9% in the
pre-MCCV period to 12.5% in the post-MCCV period (p = 0.18).
Age-speciﬁc incidence of serogroup C disease also changed
between the pre- and post-MCCV periods (Fig. 2). Decreases in
incidence were observed in the post MCCV period in every age
group. This decrease was  signiﬁcant in all childhood age groups,
except infants, and in some adult age groups. The largest absolute
am (2000–2004) and post-MCCV program (2005–2013) (n = 161). Annualized age-
risons were made between two time periods; before the introduction of the MCCV
two  time periods by age group were assessed for statistical signiﬁcance.
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Table  1
Serogroup C IMD  in pre-MCCV (2000–2004) and post-MCCV (2005–2013): counts, age-speciﬁc incidences, risk differences, incidence rate ratios, and relative risk reductions.
Age group Total
count
(n)
Count
pre-MCCV
(n)
Count
post-MCCV
(n)
Incidence
pre-MCCV
per 100,000
Incidence
post-MCCV
per 100,000
Risk difference
per 100,000
Incidence rate
ratio (95% CI)
Relative risk
reduction in
post-MCCV period
<1 year 4 2 2 0.30 0.16 0.14 0.53 (0.07–3.74) 0.47
1–4  years 8 6 2 0.21 0.04 0.17 0.18 (0.04–0.91) 0.82
5–11  years 19 13 6 0.23 0.06 0.17 0.28 (0.10–0.73) 0.72
12–16  years 9 8 1 0.20 0.01 0.18 0.07 (0.01–0.55) 0.93
17–21  years 23 14 9 0.34 0.11 0.23 0.32 (0.14–0.75) 0.68
22–29  years 26 11 15 0.17 0.12 0.06 0.68 (0.31–1.47) 0.32
30–44  years 28 20 8 0.14 0.03 0.10 0.23(0.10–0.53) 0.77
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p45–64  years 29 12 17 0.08 
≥65  years 15 8 7 0.11 
eduction between the two time periods was among those 17–21
ears where incidence decreased from 0.34/100,000 in the pre-
CCV era to 0.11/100,000 in the post era vaccine, yielding a risk
ifference of 0.23/100,000. As seen in Table 1, for serogroup C IMD,
dolescents 12–16 years had the lowest IRR (IRR = 0.07 [95% CI: 0.01
o 0.55]); rate decreased more than 14-fold between the two  time
eriods.
.4. Epidemiology of serogroup Y IMD  cases
Of the 187 unique serogroup Y IMD  cases, 172 (92.0%) were
atched, six had PHOL records only and nine had iPHIS records
nly. Incidence ranged from a high of 0.16 per 100,000 in 2009 to a
ow of 0.04 per 100,000 in 2012. Although there were no signiﬁcant
hanges in incidence over the entire surveillance period from 2000
o 2013 (1.6% reduction per year [95% CI: −1.9 to 5.1]) nor during
he pre-program period between 2000 and 2008 (0.6% increase per
ear [95% CI: −6.6 to 7.3]), there was a signiﬁcant decrease (19.8%
eduction per year [95% CI: 4.7 to 32.6]) in serogroup Y IMD  between
009 and 2013, the immunization program period. The median age
f serogroup Y cases was 47.3 years (range: eight weeks to 98 years),
ith no change during the observation period (p = 0.72). Half of the
ases (50.0%) were female. Immunization status was  known for 18
f 187 cases (9.6%). Among these, 14 had not received any meningo-
occal vaccine and four were immunized with MCCV; none had
eceived MCV4.Outcome was unknown for six of the 187 serogroup Y IMD  cases,
ho ranged in age from two months to 75 years. Fifteen of 181
erogroup Y cases with known outcome died (CFR = 8.3%). In sen-
itivity analyses assuming all six serogroup Y cases with unknown
ig. 3. Annualized age-speciﬁc incidence of serogroup Y IMD in Ontario, pre-MCV4 progr
peciﬁc  incidences per 100,000 population of serogroup Y IMD  by age in Ontario. Compa
rogram in 2000–2009 and post MCV4 program in 2010–2013. Differences between the t 0.03 0.63 (0.30–1.33) 0.37
 0.06 0.41 (0.15–1.13) 0.59
outcome either lived or died, CFR varied from 8.0% (15 deaths) to
11.2% (21 deaths). If the 101 unspeciﬁed serogroup cases, eight of
which died, had been serogroup Y, CFR would have been essentially
unchanged (8.0%, 23/288). For serogroup Y cases with known out-
come, CFR did not vary with age (p = 0.25) nor between the two  time
periods (CFR 6.7% pre-MCV4 and non-signiﬁcantly greater [13.0%]
post-MCV4 [p = 0.17]).
Age distribution did not change comparing the pre- and post-
MCV4 periods (Fig. 3). The peak incidence of serogroup Y IMD
in 2009 shown in Fig. 1 was  driven by children 0–4 years and
young adults 17–21 years as these age groups had incidences of
0.42 and 0.44/100,000, respectively, that year. Rates of serogroup Y
IMD  among adolescents and young adults (12–16 years and 17–21
years) were lower in the post- versus pre-MCV4 periods; a non-
signiﬁcant decrease. Likewise, serogroup Y IRRs were 0.66 (95% CI:
0.19 to 2.32) and 0.65 (95% CI: 0.24 to 1.74) for persons 12–16 and
17–21 years, respectively (Table 2). As shown in Fig. 3 and Table 2,
there were minimal non-signiﬁcant differences between eras for
children <1 year and children 1–4 years.
4. Discussion
In our analysis of vaccine-preventable IMD  in Ontario over 14
years, the incidence of serogroup C IMD  has decreased signiﬁ-
cantly over time and between the pre- and post-program periods.
Although rates are lower in the post MCV4 period for adolescents
and young adults, there have been no signiﬁcant changes in the rate
of serogroup Y IMD  since the introduction of the MCV4 program.
Serogroup C results suggest immunization program impact at
the population level among those eligible and ineligible for the
am (2000–2009) and post-MCV4 program (2010–2013) (n = 187). Annualized age-
risons were made between two time periods; before the introduction of the MCV4
wo  time periods by age group were assessed for statistical signiﬁcance.
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Table 2
Serogroup Y IMD  in pre-MCV4 (2000–2009) and post-MCV4 (2010–2013): counts, age-speciﬁc incidences, risk differences, incidence rate ratios, and relative risk reductions.
Age group Total
count
Count
pre-MCV4
Count
post-MCV4
Incidence
pre-MCV4
per 100,000
Incidence
post-MCV4
per 100,000
Risk difference
per 100,000
Incidence rate
ratios (95% CI)
Relative risk
reduction in
post-MCV4 period
<1 year 7 5 2 0.37 0.36 0.02 0.96 (0.19–4.94) 0.04
1–4  years 7 5 2 0.09 0.09 0.00 0.98 (0.19–5.04) 0.02
5–11  years 6 6 0 0.06 0.00 0.06 0 (n/a) 1.00
12–16  years 15 12 3 0.14 0.09 0.05 0.66 (0.19–2.32) 0.34
17–21  years 23 18 5 0.21 0.14 0.08 0.65 (0.24–1.74) 0.35
22–29  years 12 9 3 0.07 0.05 0.02 0.74 (0.20–2.72) 0.26
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45–64  years 46 32 14 0.10 
≥65  years 52 40 12 0.25 
CCV program. Decrease in incidence among age groups not eli-
ible for the MCCV program (e.g. 77% decrease among persons
0–44 years) suggests herd effects. It is, however, important to note
ecreasing rates of serogroup C IMD  prior to the introduction of the
CCV program. This may  have been due to return to baseline fol-
owing outbreaks in 2001, private purchase of MCCV before it was
ublicly-funded, or other factors including expected variability in
ncidence. Despite these alternate explanations, we  believe we  have
emonstrated vaccine program impact given sustained reductions
n serogroup C IMD, including rates near zero in 2012 and 2013 and
arge relative risk reductions among children 1–4 years (82%) and
2–16 years (93%).
Although it was lower in the post-MCCV period, the overall CFR
or serogroup C IMD  was 17.4%. CFR should be interpreted with cau-
ion given the possible impact of cases with missing outcome and
issing serogroup, as seen in our sensitivity analysis. Nonetheless,
his CFR is a reminder of the severity of serogroup C IMD.
Serogroup Y IMD, while less frequently fatal than serogroup
, is now the most common among the four IMD  serogroups
reventable by Ontario’s current publicly-funded meningococcal
accination program. While overall and age-speciﬁc incidences did
ot decrease signiﬁcantly, we detected a non-signiﬁcant decrease
n serogroup Y IMD  in the age-eligible group after the MCV4 pro-
ram was implemented. This may  suggest an early impact of the
CV4 adolescent program but may  also be a secular trend unre-
ated to immunization. Given only three years of data since the
CV4 program was implemented, it is too early to draw ﬁrm con-
lusions regarding MCV4 program impact.
Data linkage highlighted challenges, opportunities, and recent
mprovements in meningococcal surveillance in Ontario. Match-
ng of the two datasets improved over time, which may  be due
o enhanced surveillance activities conducted since 2011. This
ay  also explain the slightly larger proportion matched and bet-
er immunization information for serogroup Y versus serogroup C
hose incidence was very low in the latter part of the observation
eriod. Cases with unspeciﬁed serogroup, most common among
nmatched iPHIS cases, and unknown outcome limit our ability to
raw ﬁrm conclusions with respect to these variables.
This surveillance study has a number of other limitations.
ecause IMD  is rare, overall rates were low leading to inher-
nt statistical instability of small numbers and results should
e interpreted with caution. The availability of PCR since 2008
ay  have improved our ability to microbiologically conﬁrm IMD
iagnosis and created an increase in conﬁrmed cases. For both
erogroups C and Y IMD, the proportion of cases detected by PCR
ncreased between their respective pre- and post-program periods
Serogroup C: from 7.45% to 16.4%; Serogroup Y: 4.3% to 8.5%). It
s reassuring that despite better testing (i.e. PCR) later in the study
eriod, we demonstrated decreases in IMD.
Serogroup could not be identiﬁed for 96 of 141 IMD  cases
resent in iPHIS but not matched to PHOL data (68.0%). We  sus-
ect that most of these unmatched iPHIS cases were identiﬁed05 −0.01 1.21 (0.46–3.19) −0.21
09 0.01 0.91 (0.48–1.70) 0.09
15 0.09 0.62 (0.33–1.19) 0.38
as meningococcus at local laboratories but not referred to PHOL
for serogrouping. Unspeciﬁed serogroup information would impact
trend analyses if the cases with serogroup unspeciﬁed had a differ-
ential distribution. Missing serogroup information among cases not
in the PHOL dataset illustrates the important role of the provincial
reference laboratory in the provision of accurate surveillance.
Our study was  not designed to assess the impact of privately
available MCCV or MCV4. Uptake of either vaccine during periods of
private availability is not known. We  could not assess the impact of
private purchase of MCV4, which may  occur over a wider age-range
than the grade seven program targets, given that three MCV4 vac-
cines Menactra® (Sanoﬁ Pasteur), Nimenrix® (Glaxo Smith Kline)
and MenveoTM (Novartis) are available for children as young as nine
months [8–10].
Our analysis is based on reportable disease surveillance data
entered locally and analyzed provincially. Records were frequently
missing clinical information and vaccination status. We  were not
able to explore risk factors, the clinical syndrome at presentation,
nor the sequelae of IMD. We  also could not perform any detailed
analyses related to vaccination status or changes in vaccination cov-
erage over time. For example, we  are unable to provide an overall
estimate of vaccine effectiveness to compare to that found in Que-
bec, Canada, (87.4%, 95% CI: 75.4–94.2%) [11]. Ontario has no means
of assessing coverage at age two years and there are no publicly-
available estimates of meningococcal conjugate vaccine coverage
when either program was  introduced. The aforementioned data
quality issues highlight the need for improved reportable diseases
data collection, better integration of laboratory data with public
health data, and the need for a comprehensive provincial immu-
nization registry.
The changing epidemiology of IMD  in Ontario could have future
implications for meningococcal vaccination programs. Serogroup
Y IMD  has been more common than serogroup C IMD since 2007
and current rates of serogroup Y disease among children 1–4 years
are similar to pre-MCCV rates of serogroup C IMD  in the same age
group. It may  be time to consider use of MCV4, rather than MCCV,
for routine toddler immunization.
Fourteen years of population-based surveillance appear to
demonstrate MCCV program impact in Ontario. Further data, and a
longer observation period, will be required to assess the impact of
the MCV4 program and to evaluate the changing dynamics of the
meningococcus as a result of meningococcal vaccination programs.
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